NASDAQ · ONCY

Oncolytics Biotech Inc

Closing price · Nov 13, 2026 $0.37

Last insider buy price $0.96 Paid by CEO, Director Jared Kelly on Mar 12, 2026 (Form 4). Not today's price.

Latest quarter · ended Sep 30, 2026

Cash got weaker

descriptionFiled Nov 13, 2026

Cash from operationsWorse

−$6.92M

Mar '25Sep '26

vs. −$4.84M a year ago

Share countDiluting

+17.2%

Mar '25Sep '26

136.14M shares vs. 116.13M a year ago

Numbers come from the company's own 10-Q and 10-K reports filed with the SEC. Each bar is one quarter, oldest on the left. The colored bar is the latest. Hover over or tap a bar to see its number.

Smart money pulse

What insiders and funds are doing

Mixed Insiders: as of Nov 13 Funds: as of Jun 30, 2026

info
No real insider sales in 12 months. Planned 10b5-1 sales and tax withholding are left out.

−100 means everyone selling, +100 everyone buying. This is data, not advice.

How the Pulse works

Pulse runs from −100 (everyone selling) to +100 (everyone buying). Half comes from insiders: real buyers vs. real sellers in the last 90 days (Form 4). Half comes from funds: funds that bought vs. funds that sold last quarter (13F). 13F is a snapshot of long positions on the last day of the quarter, filed up to 45 days later. It does not show short positions or trades since then.

Who owns it

77 funds report owning ONCY, up from 58

Holdings as of Jun 30, 2026

New29

Added10

Held30

Trimmed8

Sold out10

Insider trades · last 12 months

Real buys and sales

● Open-market buy● Open-market sale

Last 12 months. No real trades in the last 6.

Showing 14 real trades. Bigger dot means a bigger trade.

Real trades, newest first

Mar 12 Jared Kelly CEO, Director Open-market buy $4.85K 5,050 sh at $0.96

Mar 11 James Parsons Director Open-market buy $10.3K 10,000 sh at $1.03

Feb 12 Bernd Seizinger Past buys: 0 of 3 beat Director Open-market buy $34K 40,000 sh at $0.85

Feb 12 Patricia Andrews Director Open-market buy $30.4K 35,400 sh at $0.86

Feb 12 Wayne Pisano Director Open-market buy $25.2K 30,000 sh at $0.84

Feb 12 Jared Kelly CEO, Director Open-market buy $24.8K 29,500 sh at $0.84

Feb 12 Deborah Brown Director Open-market buy $21.2K 25,000 sh at $0.85

Feb 12 Kirk Look CFO Open-market buy $10.1K 12,000 sh at $0.84

Feb 12 Thomas Heineman Chief Medical Officer Open-market buy $10.1K 12,132 sh at $0.83

Feb 12 Allison Hagerman VP, Product Development Open-market buy $8.3K 10,000 sh at $0.83

Show 4 older real trades

Feb 11 Bernd Seizinger Past buys: 0 of 3 beat Director Open-market buy $49.8K 60,000 sh at $0.83

Feb 11 Andrew Aromando Chief Business Officer Open-market buy $25.5K 29,600 sh at $0.86

Feb 11 Jared Kelly CEO, Director Open-market buy $4.7K 5,600 sh at $0.84

Jan 16 Bernd Seizinger Past buys: 0 of 3 beat Director Open-market buy $104K 100,000 sh at $1.04

"Past buys: 2 of 3 beat" means this insider bought stock in 3 earlier quarters, and in 2 of them what they bought did better than the typical stock over the next 6 months. A past record is data, not a forecast.

Showing every filing. Dashed circles are routine: grants, tax withholding, option exercises and planned sales.

Top holders

Biggest funds in ONCY

As of Jun 30, 2026

Fund	Owns	Value	Change
Marshall Wace, LLP	0.5%	$708K	−13%
XTX Topco Ltd	0.2%	$248K	+138%
Seeds Investor LLC	0.2%	$245K	Same
International Assets Investment Management, LLC	0.1%	$181K	New
Connective Capital Management, LLC	0.1%	$176K	New

"Owns" is shares reported divided by shares outstanding.